Pear Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$134M
Industry:Healthcare
Founded:2013
Lead Investor(s):Temasek

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Pear Therapeutics's estimated annual revenue is currently $51.3M per year.
  • Pear Therapeutics received $64.0M in venture funding in January 2019.
  • Pear Therapeutics's estimated revenue per employee is $270,000
  • Pear Therapeutics's total funding is $134M.

Employee Data

  • Pear Therapeutics has 190 Employees.
  • Pear Therapeutics grew their employee count by 5% last year.
  • Pear Therapeutics currently has 23 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Till
$24.6M917%N/AN/A
Ellenhorn
$20M747%N/AN/A
The Psychologic...
$17.8M6612%N/AN/A
Child and Famil...
$21.9M817%N/AN/A
Futures Behavio...
$14.6M544%N/AN/A
The Brien Cente...
$50.5M1879%N/AN/A
The Brookline C...
$11.3M428%N/AN/A
ABACS
$32.1M11913%N/AN/A
RIVER VALLEY CO...
$27.5M1026%N/AN/A
Behavioral Conn...
$12.7M4734%N/AN/A
Missing a competitor? Contribute!?
Submit

At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSETĀ®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.

keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security

190

Number of Employees

$51.3M

Revenue (est)

23

Current Jobs

5%

Employee Growth %

$134M

Total Funding

N/A

Valuation

N/A

Accelerator

B2C

Type

Executive Contacts

NameTitleEmail
Michael PaceVP, Market Access, Value & EvidenceEmail Available
Brian PrunierVP Patient ServicesEmail Available
Joy PatermoRegional Business DirectorEmail Available
Lin SongDirector Of SoftwareEmail Available
Jordie ValdesDirector Of MarketingEmail Available
Kristin NienhuisOperations Manager
Travis BlountRegional Business DirectorEmail Available
Hilary LudererDirector Of Translational And Clinical ResearchEmail Available
Holly WebbDirector of Software Quality AssuranceEmail Available
Michael FurgasonSenior Product ManagerEmail Available

Pear Therapeutics News

09/03/2019 - Digital therapeutics have potential but commercial success unproven

Several companies, including Pear Therapeutics and Dthera, are taking a wildly different approach: digital therapeutics. These are pieces of ...

09/08/2019 - Global Digital Therapeutic Devices Market 2023 by Growth Factors, Applications, Regional Analysis, Key Players Proteus, Omada Health, WellDoc, Dthera, Virta Health, Pear Therapeutics, BioTelemetry,

Global Digital Therapeutic Devices Market 2023 by Growth Factors, ... Virta Health, Pear Therapeutics, BioTelemetry, Blue Mesa Health, M&A ...

09/03/2019 - Global Digital Therapeutics and Their Impact on Healthcare Market 2019-2026 | Top key players are Big Health,Pear Therapeutics,Kaia Health,Propeller,Teva,My mhealth,Omada Health,Happify

Global Digital Therapeutics and Their Impact on Healthcare Market 2019-2026 | Top key players are Big Health,Pear Therapeutics,Kaia Health ...

Pear Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-03-23$UndisclosedUndisclosed5AM VenturesArticle
2016-02-05$20.0MUndisclosed5AM VenturesArticle
2018-01-03$50.0MBTemasekArticle
2019-01-07$64.0MCTemasekArticle